NEW YORK, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company ...

Check the time stamp on this data. Updated AI-Generated Signals for Keros Therapeutics Inc. (KROS) available here: KROS. Type a few symbols and Take a Trial. The signals for these will appear ...

Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Fintel reports that on January 21, 2025, Cantor Fitzgerald downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) ...

Fintel reports that on January 17, 2025, Wedbush downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from ...

Keros Therapeutics Inc (KROS) stock saw a decline, ending the day at $11.39 which represents a decrease of $-0.02 or -0.18% from the prior close of $11.41. The stock opened at $11.31 and touched a low ...

Subscribers also receive market analysis, stock correlation tools, macroeconomic observations, timing tools, and protection from market crashes using Evitar Corte.

Keros Therapeutics (NASDAQ:KROS – Get Free Report) had its target price cut by equities research analysts at Oppenheimer from ...

Keros Therapeutics Inc (KROS) stock saw a modest uptick, ending the day at $10.86 which represents a slight increase of $0.34 or 3.23% from the prior close of $10.52. The stock opened at $11 and ...

A downtrend has been apparent in Keros Therapeutics, Inc. (KROS) lately with too much selling pressure. The stock has declined 36.2% over the past four weeks. However, given the fact that it is ...